Eli Lilly & Co v Pfizer Overseas Pharmaceuticals

In the case of Eli Lilly & Co v Pfizer Overseas Pharmaceuticals, the dispute centered on the validity and infringement of a patent related to a pharmaceutical product used for the treatment of impotence. The patent in question was held by Pfizer Overseas Pharmaceuticals, while Eli Lilly & Co was alleged to have infringed the patent through its product, Cialis. The matter was adjudicated in a lower court, where the central legal issues involved the validity of claim 10 of the patent and whether Eli Lilly's conduct constituted an infringement of this claim.

The court examined the validity of claim 10, which pertained to the use of compounds with a specific physiological effect. The court concluded that claim 10 was invalid because it did not disclose an inventive step, given the common general knowledge in the field, particularly considering certain scientific publications that predated the relevant filing date. Additionally, the court found that claim 10 was not fairly based on the matter disclosed in the patent specification. Despite these findings, the court also determined that claim 10 was novel and not invalid for other reasons such as insufficiency, failure to disclose the best method, not being a manner of manufacture, or being obtained by a false suggestion. Furthermore, the court ruled that if claim 10 were valid, Eli Lilly's sales of Cialis would have constituted an infringement.

In summary, the court found that while claim 10 was invalid, Pfizer had succeeded on other issues, and if the claim were valid, Eli Lilly's actions would have constituted an infringement. The proceeding was adjourned to a later date, and counsel were directed to submit minutes of proposed orders.